The Carboxy-Terminal Calcium Binding Sites of Calmodulin Control Calmodulin's Switch from an Activator to an Inhibitor of RYR1
Calcium and calmodulin both regulate the skeletal muscle calcium release channel, also known as the ryanodine receptor, RYR1. Ca2+-free calmodulin (apocalmodulin) activates and Ca2+-calmodulin inhibits the ryanodine receptor. The conversion of calmodulin from an activator to an inhibitor is due to C...
Saved in:
Published in: | Biochemistry (Easton) Vol. 40; no. 41; pp. 12430 - 12435 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
American Chemical Society
16-10-2001
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Calcium and calmodulin both regulate the skeletal muscle calcium release channel, also known as the ryanodine receptor, RYR1. Ca2+-free calmodulin (apocalmodulin) activates and Ca2+-calmodulin inhibits the ryanodine receptor. The conversion of calmodulin from an activator to an inhibitor is due to Ca2+ binding to calmodulin. We have previously shown that the binding sites for apocalmodulin and Ca2+-calmodulin on RYR1 are overlapping with the Ca2+-calmodulin site located slightly N-terminal to the apocalmodulin binding site. We now show that mutations of the calcium binding sites in either the N-terminal or the C-terminal lobes of calmodulin decrease the affinity of calmodulin for the ryanodine receptor, suggesting that both lobes interact with RYR1. Mutation of the two C-terminal Ca2+ binding sites of calmodulin destroys calmodulin's ability to inhibit ryanodine receptor activity at high calcium concentrations. The mutated calmodulin, however, can still bind to RYR1 at both nanomolar and micromolar Ca2+ concentrations. Mutating the two N-terminal calcium binding sites of calmodulin does not significantly alter calmodulin's ability to inhibit ryanodine receptor activity. These data suggest that calcium binding to the two C-terminal calcium binding sites within calmodulin is responsible for the switching of calmodulin from an activator to an inhibitor of the ryanodine receptor. |
---|---|
Bibliography: | This work is supported by grants from the Muscular Dystrophy Association (MDA), the National Institutes of Health (AR41802 and AR44864 to S.L.H., and GM49155), and the Robert A. Welch Foundation (C-1119 to K.B.). istex:0BED1CF71AE4D31FF565E4B8307BD466027F3884 ark:/67375/TPS-9M1J4DTL-8 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0006-2960 1520-4995 |
DOI: | 10.1021/bi011078a |